Facebook Twitter Instagram LinkedIn RSS
    Facebook Twitter Instagram LinkedIn RSS
    SHOOTonline SHOOTonline SHOOTonline
    Register
    • Home
    • News
      • MySHOOT
      • Articles | Series
        • Best work
        • Chat Room
        • Director Profiles
        • Features
        • News Briefs
        • “The Road To Emmy”
        • “The Road To Oscar”
        • Top Spot
        • Top Ten Music Charts
        • Top Ten VFX Charts
      • Columns | Departments
        • Earwitness
        • Hot Locations
        • Legalease
        • People on the Move
        • POV (Perspective)
        • Rep Reports
        • Short Takes
        • Spot.com.mentary
        • Street Talk
        • Tool Box
        • Flashback
      • Screenwork
        • MySHOOT
        • Most Recent
        • Featured
        • Top Spot of the Week
        • Best Work You May Never See
        • New Directors Showcase
      • SPW Publicity News
        • SPW Release
        • SPW Videos
        • SPW Categories
        • Event Calendar
        • About SPW
      • Subscribe
    • Screenwork
      • Attend NDS2024
      • MySHOOT
      • Most Recent
      • Most Viewed
      • New Directors Showcase
      • Best work
      • Top spots
    • Trending
    • NDS2024
      • NDS Web Reel & Honorees
      • Become NDS Sponsor
      • ENTER WORK
      • ATTEND
    • PROMOTE
      • ADVERTISE
        • ALL AD OPTIONS
        • SITE BANNERS
        • NEWSLETTERS
        • MAGAZINE
        • CUSTOM E-BLASTS
      • FYC
        • ACADEMY | GUILDS
        • EMMY SEASON
        • CUSTOM E-BLASTS
      • NDS SPONSORSHIP
    • Contact
    • Subscribe
      • Digital ePubs Only
      • PDF Back Issues
      • Log In
      • Register
    SHOOTonline SHOOTonline SHOOTonline
    Home » City of Chicago sues over painkiller marketing

    City of Chicago sues over painkiller marketing

    By SHOOTWednesday, June 4, 2014Updated:Tuesday, May 14, 2024No Comments1124 Views
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email

    By Carla K. Johnson, Medical Writer

    CHICAGO (AP) --

    The city of Chicago is seeking damages in a lawsuit accusing five drugmakers of deceptively marketing a class of prescription painkiller that can be highly addictive.

    The lawsuit filed Monday in Cook County Circuit Court states the city has paid nearly $9.5 million for filling opioid prescriptions since 2007. It alleges the pharmaceutical companies' marketing of opioids for long-term use to treat non-cancer pain was false, misleading and "unsupported by science."

    The suit also claims drugmakers attempted to expand the long-term use of opioids beyond the treatment of cancer pain to reap bigger profits. The damages would be determined at trial if the city were successful in its case.

    "In order to expand the market for opioids and realize blockbuster profits, (the five companies) needed to create a sea-change in medical and public perception that would permit the use of opioids for long periods of time to treat more common aches and pains, like lower back pain, arthritis, and headaches," the lawsuit states. The companies, the suit alleges, "set out to, and did, reverse the popular and medical understanding of opioids."

    Chicago's state lawsuit is strikingly similar to one filed by two California counties last month. Both lawsuits name Johnson & Johnson's Janssen Pharmaceuticals, Purdue Pharma, Actavis, Endo Health Solutions Inc., and Teva Pharmaceutical Industries' Cephalon Inc.

    Washington, D.C.-based law firm Cohen Milstein Sellers & Toll, which specializes in consumer complaints, is involved in both the California and Chicago cases.

    Chicago subpoenaed documents from the companies "to determine if we had the basis to sue," city spokeswoman Shannon Breymaier said. The city has worked with Cohen Milstein on other legal matters and the current case began more than a year ago under Chicago Mayor Rahm Emanuel's direction, she said.

    "We have been out in front of this, and were the first city to start investigating this kind of lawsuit," Breymaier said.

    Janssen spokeswoman Robyn Frenze said in an email that the company is "committed to ethical business practices and responsible promotion, prescribing and use of all our medications."

    "We're currently reviewing the complaint," Frenze said.

    Purdue Pharma spokesman Robert Josephson said the company hasn't received the complaint and has no comment. Teva Pharmaceuticals spokeswoman Denise Bradley said the company doesn't comment on pending litigation.

    The other companies named in the complaint didn't immediately respond to requests for comment from The Associated Press.

    In 2007, Purdue Pharma, which makes OxyContin, and three of its former executives agreed to pay $634 million to settle criminal and civil charges filed by the U.S. Department of Justice. The charges alleged the company misled regulators, doctors and patients about the potential for addiction and abuse.

    Purdue has since introduced a new version of OxyContin aimed at preventing abuse. It's more difficult to crush, break or dissolve.

    Mayor Emanuel released a statement criticizing drugmakers for deceiving the public about the "true risks and benefits of highly potent and highly addictive painkillers in order to expand their customer base and increase their bottom line."

    "This has led to a dramatic rise in drug addiction, overdose and diversion in communities across the nation, and Chicago is not immune to this epidemic," Emanuel said. "Today, we're saying enough is enough — it's time for these companies to end these irresponsible practices and be held accountable for their deceptive actions."

    REGISTRATION REQUIRED to access this page.

    Already registered? LOGIN
    Don't have an account? REGISTER

    Registration is FREE and FAST.

    The limited access duration has come to an end. (Access was allowed until: 2014-06-06)



    Actor Anthony Head, known for “Buffy the Vampire Slayer” and “Ted Lasso,” dies at 72

    Friday, June 5, 2026
    Anthony Head arrives for the European premiere of 'The Iron Lady' on Wednesday, Jan. 4, 2012, in London. (AP Photo/Jonathan Short, File)

    Anthony Head, the suave, smooth-voiced British actor known for roles in "Buffy the Vampire Slayer" and "Ted Lasso," has died, his family said Friday. He was 72.

    Head's daughters, actors Emily and Daisy Head, told the Press Association news agency that the actor passed away due to complications from pneumonia.

    The stage and TV performer became well known to British audiences in the 1980s as one half of a will-they, won't-they romantic couple in a series of ads for Nescafe Gold Blend instant coffee. The ads were later re-shot for a U.S. audience for Taster's Choice.

    Head achieved wider fame as librarian Rupert Giles, mentor to the title character in the cult-favorite supernatural series "Buffy the Vampire Slayer," which ran from 1997 to 2003.

    He most recently played Rupert Mannion, the villainous ex-husband of Hannah Waddingham's character Rebecca, in "Ted Lasso."

    "Our grief is far greater than the hole he has left behind, but we know his legacy will live on, in the shows he was a part of, and in the audiences that love them," his daughters said. "How lucky we are to know we are able to watch him doing what he loved, even when he is no longer with us."

    Head was born in London on Feb. 20, 1954 to Seafield Head, a documentary filmmaker, and Helen Shingler, an actor. His older brother, Murray, is also an actor.

    Other notable roles included playing Geoffrey Howe, the deputy to Prime Minister Margaret Thatcher, played by Meryl Streep, in the Oscar-winning "The Iron Lady."

    Head portrayed a prime minister himself in the sketch comedy show "Little Britain," as well as King Uther Pendragon, the father of Prince Arthur, in the "Merlin" TV series. He also appeared in "Motherland," Manchild," and "Silent Witness," along... Read More

    No More Posts Found

    MySHOOT Profiles

    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email

    Previous ArticleHungary ad tax seen as threat to press freedom
    Next Article BusterINK hires Noah Witlin as creative director
    SHOOT

    Add A Comment
    What's Hot

    Delving Into The Visual Effects For “Wednesday” and “Stranger Things”

    Friday, June 5, 2026

    Anonymous Content Expands Relationship With Comedy Director Max Barden To Include U.S. Representation

    Friday, June 5, 2026

    Saatchi & Saatchi Unveils 2026 New Creators’ Showcase At SXSW London

    Friday, June 5, 2026
    Shoot Screenwork

    Top Spot of the Week: Martin de Thurah Directs Absurdist “It’s Over” For Wealthsimple

    Friday, June 5, 2026

    Wealthsimple, director Martin De Thurah and Epoch Films return for their latest campaign, “It’s Over,”…

    Director Ivan Zacharias and TBWA\Media Arts Lab Go On A Privacy Safari To Get “Clingers” Off People’s Backs For Apple

    Thursday, June 4, 2026

    Director X, Kevin Durant and “Yes Man” Drake Come Together For A Comedic Rollout Of The Nike NOCTA KD19 Sneaker

    Wednesday, June 3, 2026

    BBDO NY and Comedian Eric Andre Hold A Focus Group For SNICKERS Peanut Butter

    Tuesday, June 2, 2026

    The Trusted Source For News, Information, Industry Trends, New ScreenWork, and The People Behind the Work in Film, TV, Commercial, Entertainment Production & Post Since 1960.

    Today's Date: Fri May 26 2023
    Facebook Twitter Instagram LinkedIn RSS
    More Info
    • Overview
    • Upcoming in SHOOT Magazine
    • Advertise
    • Privacy Policy
    • SHOOT Copyright Notice
    • SPW Copyright Notice
    • Spam Policy
    • Terms of Service (TOS)
    • FAQ
    STAY CURRENT

    SUBSCRIBE TO SHOOT EPUBS

    © 1990-2021 DCA Business Media LLC. All rights reserved. SHOOT and SHOOTonline are registered trademarks of DCA Business Media LLC.
    • Home
    • Trending Now

    Type above and press Enter to search. Press Esc to cancel.

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.